Chemotherapy and cognitive deficits: Mechanisms, findings, and potential interventions

Palliative and Supportive Care

Volumn 5, Issue 3, 2007, Pages 273-280

  Nelson, Christian J ^a   Nandy, Nina ^b   Roth, Andrew J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotheraphy; Cognitive functioning; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COGNITIVE DEFECT; FEMALE; HUMAN; PATHOPHYSIOLOGY; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; QUALITY OF LIFE;

EID: 34848828517     PISSN: 14789515     EISSN: 14789523     Source Type: Journal    
DOI: 10.1017/S1478951507000442     Document Type: Review

References (48)

1. Ahles, T.A. (2000). Chemo brain: It's not in your head. In 42nd Annual Science Writer's Seminar. Atlanta, GA: American Cancer Society.
2. Ahles, T.A. & Saykin, A. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investigation, 19, 812-820.
3. Ahles, T.A., Saykin, A.J., Furstenberb, C.T., et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493.
4. Ahles, T.A., Saykin, A.J., Noll, W.W., et al. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology, 12 612-619.
5. Barton, D. & Loprinzi, C. (2002). Novel approaches to preventing chemotherapy-induced cognitive dysfunction in breast cancer: The art of the possible. Clinical Breast Cancer, 3(Suppl. 3), S121-S127.
6. Beard, C.M., Kokmen, E., O'Brien, P.C., et al. (1997). Risk of Alzheimer's disease among elderly patients with anemia: Population-based investigations in Olmsted County, Minnesota. Annals of Epidemiology, 7, 219-224.
7. Bender, C.M., Sereika, S.M., Berga, S.L., et al. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology, 15, 422-430.
8. Brezden, C.B., Phillips, K.A., Abdolell, M., et al. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701.
9. Cherrier, M.M., Rose, A., & Higano, C. (2003). The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. Journal of Urology, 170, 1808-1811.
10. Fillit, H.M., Butler, R.N., O'Connel, A.W., et al. (2002). Achieving and maintaining cognitive vitality with aging. Mayo Clinic Proceedings, 77, 681-696.
11. Gabrilove, J.L., Cleeland, C.S., Livingston, R.B., et al. (2001). Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. Journal of Clinical Oncology, 19, 2875-2882.
12. Galli, R.L., Shukitt-Hale, B., Youdim, K.A., et al. (2002). Fruit polyphenolics and brain aging: Nutritional interventions targeting age-related neuronal and behavioral deficits. Annals of the New York Academy of Sciences, 959, 128-132.
13. Green, H.J., Pakenham, K.I., Headley, B.C., et al. (2004). Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: A randomized controlled trial. BJU International, 93, 975-979.
14. Gultekin, S.H., Rosenfeld, M.R., Voltz, R., et al. (2000). Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain, 123, 1481-1494.
15. Haan, M.N., Shemanski, L., Jagust, W.J., et al. (1999). The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA, 282, 40-46.
16. Hampson, E. (1990). Variations in sex-related cognitive abilities across the menstrual cycle. Brain and Cognition, 14, 26-43.
17. Haskell, S.G., Richardson, E.D., & Horwitz, R.I. (1997). The effect of estrogen replacement therapy on cognitive function in women: A critical review of the literature. Journal of Clinical Epidemiology, 50, 1249-1264.
18. Hassmen, P., Ruggero, C., & Backman, L. (1992). Exercise for older women: A training method and its influences on physical and cognitive performance. European journal of applied physiology and occupational physiology, 64, 460-466.
19. Hurria, A., Rosen, C., Hudis, C., et al. (2006). Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. Journal of the American Geriatrics Society, 54, 925-931.
20. Jacobsen, RB., Thors, C.L., Cawley, M., et al. (2004). Relationship of hemoglobin levels to fatigue and cognitive functioning among cancer patients receiving chemotherapy. Journal of Pain and Symptom Management, 28, 7-18.
21. Jansen, C.E., Dodd, M., Dowling, G., et al. (2005). A meta-analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer, 104, 2222-2232.
22. Liberman, J.N., Stewart, W.F., Wesnes, K., et al. (2002). Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. Neurology, 58, 1038-1044.
23. Littlewood, T.J., Bajetta, E., Nortier, J.W.R., et al. (2001). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865-2874.
24. Lower, E., Fleishman, S., Cooper, A., et al. (2005). A phase III randomized placebo-controlled trial of the safety and efficacy of d-MPH as new treatment of fatigue and "chemobrain" in adult cancer patients. Journal of Clinical Oncology, 23 (June 1 Suppl.), 8000.
25. Maier-Lorentz, M.M. (2000). Neurobiological bases for Alzheimer's disease. Journal of Neuroscience Nursing, 32, 117-125.
26. Milward, E.A., Grayson, D.A., Creasy, H., et al. (1999). Evidence for association of anaemia with vascular dementia. NeuroReport, 10, 2377-2381.
27. Minisini, A., Atalay, G., Bottomley, A., et al. (2004). What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncology, 5, 273-282.
28. Meyers, C.A., Weitzner, M.A., Valentine, A.D., et al. (1998). Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. Journal of Clinical Oncology, 16, 2522-2527.
29. O'Shaughnessy, J. (2003). Chemotherapy-related cognitive dysfunction in breast cancer. Seminars in Oncology Nursing, 19, 17-24.
30. O'Shaughnessy, J., Vukelka, S., Savin, M., et al. (2002). Impact of epoetin alfa on cognitive function, asthenia, and quality of life in women with breast cancer receiving adjuvant or neoadjuvant chemotherapy: Analysis of 6-month follow-up data. Breast Cancer Research and Treatment, 19(Suppl 2), 17-24.
31. Perkins, A.J., Hendrie, H.C., Callahan, M.C., et al. (1999). Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. American Journal of Epidemiology, 150, 37-44.
32. Quayhagen, M.P., Quayhagen, M., Corbeil, R.R., et al. (1995). A dyadic remediation program for care recipients with dementia. Nursing Research, 44, 153-159.
33. Ramassamy, C., Averill, D., Beffert, U., et al. (1999). Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radical Biology & Medicine, 27, 544-553.
34. Reichenberg, A., Yirmiya, R., Schud, A., et al. (2001). Cytokine-associated emotional and cognitive disturbances in humans. Archives of General Psychiatry, 58, 445-452.
35. Richard, F. & Amouyel, P. (2001). Genetic susceptibility factors for Alzheimer's disease. European Journal of Pharmacology, 412, 1-12.
36. Rikli, R.E. & Edwards, D.J. (1991). Effects of a three-year exercise program on motor function and cognitive processing speed in older women. Research quarterly for exercise and sport, 62, 61-67.
37. Rozans, M., Dreisbach, A., Lertora, J., et al. (2002). Palliative uses of methylphenidate in patients with cancer: A review. Journal of Clinical Oncology, 20, 335-339.
38. Schagen, S.B., van Dam, F.S., Muller, M.J., et al. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.
39. Scherwath, A., Mehnert, A., Schleimer, B., et al. (2006). Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: Evaluation of long-term treatment effects. Annals of Oncology, 17, 415-423.
40. Schooler, C., Mulatu, M.S., & Oates, G. (1999). The continuing effects of substantively complex work on the intellectual functioning of older workers. Psychology of Aging, 14, 483-506.
41. Shilling, V., Jenkins, V., Fallowfield, L., et al. (2003). The effects of hormone therapy on cognition in breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 86, 405-412.
42. Sood, A., Barton, D.L., & Loprinzi, C. (2006). Use of methylphenidate in patients with cancer. American Journal of Hospice & Palliative Care, 23, 35-40.
43. Subhan, Z. & Hindmarch, I. (1984). The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. International Journal of Clinical Pharmacology Research, 4, 89-93.
44. Tardiff, B.E., Newman, M.F., Saunders, A.M., et al. (1997). Preliminary report of a genetic basis for cognitive decline after cardiac operations. The Neurologic Outcome Research Group of the Duke Heart Center. Annals of Thoracic Surgery, 64, 715-720.
45. van Dam, F.S., Schagen, S.B., Muller, M.J., et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.
46. Wefel, J.S., Lenzi, R., Theriault, R.L., et al. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer, 100, 2292-2299.
47. Weitzner, M.A., Meyers, C.A., & Valentine, A.D. (1995). Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 347-350.
48. Wieneke, M.H. & Dienst, E.R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology, 4, 61-65.